Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD
Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-15
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of ensartinib on adjuvant therapy guided by MRD in IA3-IIIB (T3N2) stage ALK-positive non-small cell lung cancer patients.